Transplacental methadone exposure and risk of Neonatal Opioid Withdrawal Syndrome

Abstract

AbstractStudy ObjectiveNeonatal opioid withdrawal syndrome (NOWS) is a condition that often occurs in neonates born to mothers who received methadone treatment for opioid use disorder during pregnancy. Early identification and treatment of infants at risk of NOWS may improve clinical outcomes. The purpose of this study was to evaluate whether maternal and umbilical cord plasma concentrations of methadone and its metabolite, 2‐ethylidene‐1,5‐dimethyl‐3,3‐diphenylpyrrolidine (EDDP), could predict the need for NOWS treatment.DesignSingle‐center prospective study.SettingUniversity of Michigan Neonatal Intensive Care Unit.PatientsThe study included 11 opioid‐dependent mother–infant dyads, where the mothers were treated with methadone at 34 weeks' gestation or later.InterventionMaternal and cord blood samples were collected from the study participants.Measurements and Main ResultsMaternal and cord plasma concentrations of methadone and EDDP were determined. Six out of the 11 infants required treatment for NOWS. Maternal methadone plasma concentrations were comparable between infants requiring and not requiring NOWS treatment (329.1 ± 229.7 ng/mL vs. 413.2 ± 329.8 ng/mL). However, the average cord plasma methadone concentration in infants who did not require NOWS treatment was 2.9‐fold higher than in those who required the treatment (120.0 ± 88.6 ng/mL vs. 40.9 ± 24.4 ng/mL), although the difference was not statistically significant. The ratios of maternal‐to‐cord methadone plasma concentrations were significantly higher in patients who required treatment for NOWS compared with those who did not (7.7 ± 1.9 vs. 3.5 ± 1.6, p = 0.003). Maternal and cord plasma EDDP concentrations and the maternal‐to‐cord plasma EDDP concentration ratios did not differ between patients who required and did not require treatment for NOWS.ConclusionsThe results suggest that methadone permeability across the blood–placental barrier may affect in utero exposure to methadone, and the maternal‐to‐cord methadone plasma concentration ratio could be a potential biomarker for predicting the need for NOWS treatment.